Globus Medical (GMED) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Reiterates Outperform Following Globus Medical's (GMED) Strong 4Q
February 25, 2016 7:26 AM ESTLeerink Partners maintained an Outperform rating on Globus Medical (NYSE: GMED), and cut the price target to $29.00 (from $32.00), following the company's 4Q earnings report. Revenue of ~$142.6M was in line with the January preannouncement and ~$4M above the Street. GMED also delivered... More
